Welcome to our dedicated page for Pelthos Therapeutics news (Ticker: PTHS), a resource for investors and traders seeking the latest updates and insights on Pelthos Therapeutics stock.
Pelthos Therapeutics Inc. (PTHS) generates news primarily around its commercial dermatology portfolio and corporate development activities. As a biopharmaceutical company focused on therapeutic products for unmet patient needs, much of its coverage relates to the launch and market uptake of ZELSUVMI (berdazimer) topical gel, 10.3%, an FDA-approved at-home treatment for molluscum contagiosum in adults and pediatric patients one year of age and older.
Investors following Pelthos can expect regular updates on product commercialization milestones, including prescription trends, prescriber adoption, and payer access for ZELSUVMI. Company press releases have highlighted commercial agreements with pharmacy benefit managers and group purchasing organizations that expand formulary coverage and patient access, as well as educational initiatives such as the Moms Against Molluscum movement aimed at caregivers managing molluscum contagiosum.
News flow also covers portfolio expansion. Pelthos has announced acquisitions of Xepi (ozenoxacin) Cream, 1%, an FDA-approved topical treatment for impetigo, and Xeglyze (abametapir), an FDA-approved topical treatment for head lice infestation. These transactions, together with planned product relaunch timelines, feature prominently in company communications as Pelthos builds a broader cutaneous infectious disease franchise.
On the corporate and financial side, Pelthos issues releases on quarterly financial results, private financings, and credit facilities. Examples include senior secured convertible notes with investors including Ligand Pharmaceuticals and a senior secured term loan facility with Horizon Technology Finance Corporation, both described as supporting commercialization of ZELSUVMI and the integration of additional products. Governance and investor relations updates, such as board appointments and participation in healthcare and investor conferences, also appear in the company’s news stream.
For readers and investors, the Pelthos news page offers a consolidated view of these developments, providing context on how the company is executing its strategy in molluscum contagiosum, impetigo, and head lice, and how financing and partnerships are aligned with its commercial objectives.
Pelthos Therapeutics (NYSE American: PTHS) has launched ZELSUVMI™ (berdazimer) topical gel 10.3%, marking a significant milestone as the first and only FDA-approved at-home treatment for molluscum contagiosum. The novel nitric oxide-releasing gel, which received FDA Novel Drug designation in January 2024, is now commercially available through prescription.
In Phase 3 clinical trials involving 891 patients, ZELSUVMI demonstrated complete clearance in 33% of patients compared to 19.7% in the control group at week 12, with some patients showing results within two weeks. The treatment targets an estimated 16.7 million affected people in the United States, with up to 6 million new cases annually.
To support the launch, Pelthos has deployed 50 sales territory managers nationwide and implemented the ZelsuvmiGo patient support program to facilitate patient access and education.
Pelthos Therapeutics (NYSE:PTHS) has completed its merger with Channel Therapeutics and secured a $50.1 million private placement. The combined company will begin trading on the NYSE American exchange under the ticker PTHS on July 2, 2025.
The private placement, led by Murchinson Ltd., includes the cancellation of $18.8 million in bridge capital. Pelthos will focus on launching ZELSUVMI™, an FDA-designated novel drug for molluscum contagiosum infections, which affects approximately 16.7 million people in the United States. The medication is the first prescription treatment that can be administered at home.
The company will also evaluate NaV 1.7 development programs for various pain treatments. Scott Plesha will serve as CEO, while former Channel Therapeutics CEO Frank Knuettel II becomes CFO of the combined entity.